Translational Development Acquisition Q2 FY26 net income falls 41.66% to $946,982; trust account dividends slip 10.87% to $1.64 million

• Translational Development Acquisition posted Q2 net income of $946,982, down 41.66% from a year earlier.
• Dividends on trust-held marketable securities fell 10.87% to $1.64 million; results also included a $36,138 unrealized loss.
• General and administrative costs climbed to $661,050 from $221,127, pressuring quarterly profit.
• For the first half, net income slipped 26.62% to $2.28 million on $3.28 million of trust dividends.
• TDAC agreed to a $50 million share subscription tied to its planned ProLogium deal; trust assets totaled $157.26 million at June 30.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Translational Development Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-097093), on August 14, 2026, and is solely responsible for the information contained therein.